Apogee Therapeutics (APGE)

• Market cap: $10.1B
• 1 day: -0.08%
• 5 days: -0.02%
• 1 month: 1.18%
• 3 months: 57.16%
• 6 months: 89.8%
• Year to date: 77.05%
• 1 year: 238.3%
• 5 years: 531.98%
• 10 years: 531.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Employees: 261